戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 cted probability that they would be users of antipsychotic drugs).
2 ive to treatment with clozapine, an atypical antipsychotic drug.
3  within 90 days of prescription for atypical antipsychotic drugs.
4 mplicate NRXN1 in the therapeutic actions of antipsychotic drugs.
5 pectrum disorders who had chosen not to take antipsychotic drugs.
6 ectrum disorders who have chosen not to take antipsychotic drugs.
7 phrenia that are often resistant to existing antipsychotic drugs.
8 ession influences the therapeutic effects of antipsychotic drugs.
9 ed as models for the characterization of new antipsychotic drugs.
10 ent in patients undergoing first exposure to antipsychotic drugs.
11 verbal hallucinations that are refractory to antipsychotic drugs.
12 ia, as well as in the mechanism of action of antipsychotic drugs.
13  potential target for the development of new antipsychotic drugs.
14 preclinical animal models used to screen new antipsychotic drugs.
15  mesolimbic selectivity of second-generation antipsychotic drugs.
16  of possible anti-inflammatory roles of some antipsychotic drugs.
17 n in patients with SCZ before treatment with antipsychotic drugs.
18 in general, will be useful as broad-spectrum antipsychotic drugs.
19 espectively, and 186,600 matched nonusers of antipsychotic drugs.
20 cs and the atypical and glutamate classes of antipsychotic drugs.
21 hibitors, a phospholipase C inhibitor, and 2 antipsychotic drugs.
22 tor 2 (DRD2), the best-established target of antipsychotic drugs.
23 istant to treatment with dopamine antagonist antipsychotic drugs.
24  than did patients assigned to either of the antipsychotic drugs.
25 tual disability and it is often treated with antipsychotic drugs.
26 r country's regulations regarding the use of antipsychotic drugs.
27  and is a potential target of action of some antipsychotic drugs.
28 peutic drugs, including typical and atypical antipsychotic drugs.
29 not smoke and were concurrently treated with antipsychotic drugs.
30            These effects were ameliorated by antipsychotic drugs.
31 ubtype (D2) are important sites of action of antipsychotic drugs.
32 receptors are the best-established target of antipsychotic drugs.
33 tion might reveal chemical targets for novel antipsychotic drugs.
34 evelopment of NT1 receptor agonists as novel antipsychotic drugs.
35  receptor blockade to that of other atypical antipsychotic drugs.
36 erebrovascular disease and use anxiolytic or antipsychotic drugs.
37 coupled receptor that is a common target for antipsychotic drugs.
38 prospective treatment with second-generation antipsychotic drugs.
39 isorders, making those receptors targets for antipsychotic drugs.
40 rapeutic efficacy in comparison with current antipsychotic drugs.
41 ch is likely to affect the mode of action of antipsychotic drugs.
42 potential biomarker of treatment response to antipsychotic drugs.
43 en suggested as a promising target for novel antipsychotic drugs.
44 d in animal models and preclinical trials of antipsychotic drugs.
45 de the discovery of safer and more efficient antipsychotic drugs.
46 , low physical activity, and side-effects of antipsychotic drugs.
47 yle risks and direct and indirect effects of antipsychotic drugs.
48 rtant target for antidepressant and atypical antipsychotic drugs.
49 peutic target for Parkinson's disease(1) and antipsychotic drugs(2).
50       We followed those who initiated use of antipsychotic drugs (9,777 FGA users and 21,164 SGA user
51                                 The atypical antipsychotic drugs (AAPDs) have markedly enhanced the t
52 ophrenia is based on evidence that the major antipsychotic drugs act by blocking dopamine D2 receptor
53 ay be useful in the preclinical screening of antipsychotic drugs acting to correct altered epigenetic
54 ody of research on dopamine as a mediator of antipsychotic drug action and putative roles for this tr
55  of schizophrenia (SCZ) both as a target for antipsychotic drug action as well as a SCZ-associated ri
56 e-related epigenetic changes that may impact antipsychotic drug action.
57          We also investigated the effects of antipsychotic drug administration on SV2A levels in Spra
58  rats depolarization block requires weeks of antipsychotic drug administration, whereas schizophrenia
59                         Atypical and typical antipsychotic drugs alter GSK-3 activity, as do drugs th
60                      Of note, currently used antipsychotic drugs ameliorate psychosis, but they are n
61 reductions, 32 strategies that augmented any antipsychotic drug and 5 strategies that augmented cloza
62 es often involves treatment with the typical antipsychotic drug and dopamine D2 receptor antagonist h
63 ompared separately for combinations with any antipsychotic drug and for combinations with clozapine.
64               The first randomized trials of antipsychotic drug and psychological interventions aimed
65 aid program with 28 858 recent initiators of antipsychotic drugs and 14 429 matched controls.
66 he relative effects of the second-generation antipsychotic drugs and an older representative agent on
67 for understanding the mechanism of action of antipsychotic drugs and drugs of abuse and may have pote
68 ently used to study both the pharmacology of antipsychotic drugs and drugs of abuse.
69 ose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-actin
70 er medications, they do suggest that typical antipsychotic drugs and lithium have contrasting effects
71 e effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition h
72 the dopamine transporter is a main target of antipsychotic drugs and predicting that dopamine transpo
73 the pharmacology of a new class of glutamate antipsychotic drugs and their crosstalk mechanism throug
74 ons in patients who fail to respond to other antipsychotic drugs, and to reduce the risk of suicide.
75                                              Antipsychotic drugs (AP) are used to treat a multitude o
76                     Haloperidol is a typical antipsychotic drug (APD) associated with an increased ri
77     Clinical research has shown that chronic antipsychotic drug (APD) treatment further decreases cor
78  in the neocortex, but only in cases without antipsychotic drug (APD) treatment; Kv3.1 levels are nor
79     Defining the mechanisms of action of the antipsychotic drug (APD), clozapine, is of great importa
80 d., Tokyo, Japan), a newly approved atypical antipsychotic drug (APD), on NMDAR synaptic function in
81            Increasing evidence suggests that antipsychotic drugs (APD) might affect brain structure d
82                                              Antipsychotic drugs (APD)s and anticonvulsant mood-stabi
83                                              Antipsychotic drugs (APDs) are best classified as typica
84   Mood stabilizers (e.g., valproic acid) and antipsychotic drugs (APDs) are commonly co-administered
85                    Most clinically available antipsychotic drugs (APDs) bind dopamine D2 receptors (D
86                                     Atypical antipsychotic drugs (APDs) have been hypothesized to sho
87                   The main class of atypical antipsychotic drugs (APDs) in current use includes the p
88                                      Current antipsychotic drugs (APDs) show efficacy with positive s
89                                     Atypical antipsychotic drugs (APDs) such as clozapine, but not th
90                             All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2
91 red imaging in cultured hippocampal neurons, antipsychotic drugs (APDs) were proposed to accumulate i
92 ted to contribute to the ability of atypical antipsychotic drugs (APDs), e.g. clozapine, risperidone,
93 alproic acid and carbamazepine, and atypical antipsychotic drugs (APDs), e.g., clozapine, quetiapine,
94                Acute treatment with atypical antipsychotic drugs (APDs), which are serotonin (5-HT)(2
95 igm shift due to development of new atypical antipsychotic drugs (APDs), with better tolerability due
96 ) NC and SZ treated with typical or atypical antipsychotic drugs (APDs).
97                                          All antipsychotic drugs are D2 antagonists, but D2 antagonis
98                             First-generation antipsychotic drugs are effective and cost effective for
99                                     Although antipsychotic drugs are effective for relieving the psyc
100                                              Antipsychotic drugs are effective in the acute treatment
101                                              Antipsychotic drugs are effective interventions in schiz
102          Although there are indications that antipsychotic drugs are increasingly used to treat child
103                                              Antipsychotic drugs are its treatment of choice, but the
104                                     However, antipsychotic drugs are not clinically effective at reve
105 ins a challenge, and the currently available antipsychotic drugs are slow acting and produce a number
106 te transporters moderate CNS availability of antipsychotic drugs are summarised.
107                                      Because antipsychotic drugs are used as mood stabilizers our stu
108                                              Antipsychotic drugs are used to treat dementia-related s
109                                              Antipsychotic drugs are usually the first line of treatm
110                                              Antipsychotic drugs are widely prescribed to elderly pat
111                                      Typical antipsychotic drugs are widely thought to alleviate the
112                 Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis,
113 macological treatments for delirium (such as antipsychotic drugs) are not effective, reflecting subst
114  of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic cat
115 tified several diphenylbutylpiperidine-class antipsychotic drugs as agents that decreased PRL-induced
116 ffectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agent
117 e incidence-rate ratio for users of atypical antipsychotic drugs as compared with users of typical an
118 ng the actions of hallucinogens and atypical antipsychotic drugs at 5-HT(2A) and 5-HT(2C) serotonergi
119  level of occupancy is lower than most other antipsychotic drugs at their efficacious doses and likel
120 s with schizophrenia who were medicated with antipsychotic drugs at their time of death display incre
121 ain changes are not explained by exposure to antipsychotic drugs but likely play a role in psychosis
122                                     Atypical antipsychotic drugs, by definition, differ from typical
123                       This demonstrates that antipsychotic drugs can attenuate AMP disruption of lear
124        We demonstrate that, like in mammals, antipsychotic drugs can suppress disruptions in zebrafis
125                           Aripiprazole is an antipsychotic drug characterized by partial agonist acti
126 dy raises the possibility of repurposing the antipsychotic drug chlorpromazine for treatment of neuro
127 , risperidone and not the prototype atypical antipsychotic drug clozapine increased the frequency of
128                           Treatment with the antipsychotic drug clozapine reverses the behavioral and
129                     As demonstrated with the antipsychotic drug clozapine, the DTome tool was effecti
130 tagonist ketanserin, and inverse agonist and antipsychotic drug clozapine.
131 tices, resembling the action of the atypical antipsychotic drug clozapine.
132 ed clinical trials comparing the efficacy of antipsychotic drugs combined with other antipsychotic or
133     At present, treatment mainly consists of antipsychotic drugs combined with psychological therapie
134 ty disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month perio
135 erable attention regarding schizophrenia and antipsychotic drug development.
136 eurotransmission is a prioritized target for antipsychotic drug development.
137  further highlight p110delta as a target for antipsychotic drug development.
138                                      Typical antipsychotic drugs do not improve this deficit while so
139                              Because current antipsychotic drugs do not provide optimal therapy, we h
140             Subjects continued their current antipsychotic drug during the trial and were nonsmokers.
141                                              Antipsychotic drug effects were explored in mice treated
142 opamine, long implicated in psychosis and in antipsychotic drug effects, is crucial in optimizing sig
143       Several lines of evidence suggest that antipsychotic drug efficacy is mediated by dopamine type
144                                              Antipsychotic drug efficacy may have decreased over rece
145 cs has been most commonly used in studies of antipsychotic drug efficacy, antidepressant drug respons
146             Here we demonstrate that chronic antipsychotic drug exposure increases nuclear translocat
147 ein levels in schizophrenia in vivo and that antipsychotic drug exposure is unlikely to account for t
148 ry management of schizophrenia regardless of antipsychotic drug exposure.
149  associated with the use of first-generation antipsychotic drugs (FGAs) compared with second-generati
150 ture model of tau aggregation and that other antipsychotic drugs (flupenthixol, perphenazine, and zot
151            Repeated administration of either antipsychotic drug for 1, 3, 7, 15, and 21 d continued t
152              There is support for the use of antipsychotic drugs for all types of psychosis in the el
153 l consideration is required when prescribing antipsychotic drugs for patients with an existing diagno
154 ectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigne
155 asingly important role in the development of antipsychotic drugs for schizophrenia and related condit
156           The dose-response relationships of antipsychotic drugs for schizophrenia are not well defin
157 ffset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggr
158 get with comparable efficacy as conventional antipsychotic drugs for treating positive and negative s
159 cytosis does not exceed that of conventional antipsychotic drugs, for which no such requirement exist
160  antimetastatic potential of penfluridol, an antipsychotic drug frequently prescribed for schizophren
161 %), antidepressants (from 1.5% to 2.6%), and antipsychotic drugs (from 0.2% to 1.2%).
162     Current users of typical and of atypical antipsychotic drugs had a similar, dose-related increase
163     Current users of typical and of atypical antipsychotic drugs had higher rates of sudden cardiac d
164                              Former users of antipsychotic drugs had no significantly increased risk
165                                          The antipsychotic drug haloperidol is an antagonist of Sigma
166 icantly potentiated the ability of a typical antipsychotic drug haloperidol, a D2 receptor antagonist
167              We previously reported that the antipsychotic drug haloperidol, a multifunctional D2-lik
168  strongly reduced cataleptic response to the antipsychotic drug haloperidol.
169           Furthermore, pretreatment with the antipsychotic drugs haloperidol and clozapine prevented
170                                              Antipsychotic drugs haloperidol and clozapine, which tar
171 D2LR signaling mediated effects of a typical antipsychotic drug, haloperidol, in inducing catalepsy b
172 ta(9)-tetrahydrocannabinol, and opiates; the antipsychotic drug, haloperidol; juvenile enrichment; su
173                             Users of typical antipsychotic drugs have an increased risk of serious ve
174                                              Antipsychotic drugs have been proven to alleviate acute
175                  Traditional D(2) antagonist antipsychotic drugs have been shown previously to reduce
176 related to Alzheimer's disease indicate that antipsychotic drugs have equivocal efficacy in improving
177 ting the effects of both psychostimulant and antipsychotic drugs; however, these drugs are known to h
178          These patients had decreased use of antipsychotic drugs immediately after the transition; th
179 -blocking effect of the mGluR2/3 agonist and antipsychotic drug in development LY404039.
180  of neurotensin(8-13), acts like an atypical antipsychotic drug in several dopamine-based animal mode
181  sudden cardiac death among current users of antipsychotic drugs in a retrospective cohort study of M
182 y of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia.
183  thought to be the primary mode of action of antipsychotic drugs in alleviating psychotic symptoms.
184 tor antagonism is a unifying property of all antipsychotic drugs in clinical use.
185  with canonical first- and second-generation antipsychotic drugs in mice.
186    We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's dise
187 xicity of both the conventional and atypical antipsychotic drugs in relation to their effects on gluc
188 tive against extrapyramidal motor effects of antipsychotic drugs in the adult life.
189 ety and efficacy of antidepressants added to antipsychotic drugs in the treatment of schizophrenia.
190 es were noted for several phenothiazine-like antipsychotic drugs, including trifluoperazine.
191                             Because atypical antipsychotic drugs increase dopamine (DA) and acetylcho
192                    Acute injection of either antipsychotic drug induced an immediate reduction in the
193 independent cohorts of subjects assessed for antipsychotic drug-induced weight gain.
194                                         Most antipsychotic drugs influence dopaminergic transmission
195 n this issue of Neuron reveal that weak base antipsychotic drugs inhibit presynaptic function in an a
196 nce strategy, a late-stage deuteration of an antipsychotic drug is described.
197                           The use of classic antipsychotic drugs is limited by the occurrence of extr
198 hophysiology of schizophrenia or exposure to antipsychotic drugs is unknown.
199  an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychot
200 operties and showed that it was inhibited by antipsychotic drugs, leading to a large body of research
201  and UNC9994 (36), which have robust in vivo antipsychotic drug-like activities.
202      The present data are consistent with an antipsychotic drug-like profile of activity for VU015210
203 ty model, compound (+)-19 showed significant antipsychotic-drug-like activity.
204  phase schizophrenia and minimal exposure to antipsychotic drugs (<2 years), who underwent resting st
205  Recent evidence suggests that some atypical antipsychotic drugs may protect against oxidative stress
206      The differential response to first-line antipsychotic drugs may reflect a different underlying n
207                                              Antipsychotic drugs might cause acutely occurring, serio
208 s underlying the response to psychedelic and antipsychotic drugs might lead to unification of the ser
209 pisode of psychosis (including N=17 who were antipsychotic drug-naive at the time of scanning) and 41
210 SIGN, SETTING, AND PARTICIPANTS: Twenty-five antipsychotic drug-naive, acutely ill patients with firs
211 ral chronic stimuli, such as drugs of abuse, antipsychotic drugs, natural rewards, and stress.
212  receptor in its inactive state bound to the antipsychotic drug nemonapride, with resolutions up to 1
213 is a putative therapeutic target of atypical antipsychotic drugs, notably clozapine, as well as some
214 addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label.
215 conducted to examine the potential effect of antipsychotic drugs on expression of the three proteins.
216                   Considering the actions of antipsychotic drugs on presynaptic and postsynaptic dopa
217  for a scientific commentary on this article.Antipsychotic drugs, originally developed to treat schiz
218 zers our studies focused on a newly-marketed antipsychotic drug, paliperidone.
219 els play a role in the therapeutic action of antipsychotic drugs, particularly risperidone, and furth
220                            We identified the antipsychotic drug perphenazine in both screens due to i
221               There was a large reduction in antipsychotic drug prescription in dementia from 22.1% (
222                                      Current antipsychotic drugs produce fairly robust clinical benef
223                                              Antipsychotic drugs remain the standard for schizophreni
224     Similar to 1 and other second-generation antipsychotic drugs, repeated treatment with 2 significa
225 morphisms in NRXN1 have been associated with antipsychotic drug response in patients with schizophren
226 ier was significantly associated with poorer antipsychotic drug response relative to the Ins/Ins geno
227  relationship between DRD2 polymorphisms and antipsychotic drug response.
228 renia, SEP-363856, a non-D2-receptor-binding antipsychotic drug, resulted in a greater reduction from
229 ntly potentiated the effects of the atypical antipsychotic drug risperidone (0.1 mg/kg) on DA, but no
230 ment) and after 1 week of treatment with the antipsychotic drug risperidone (1-week post-treatment).
231                                 The atypical antipsychotic drug risperidone, a multireceptor antagoni
232  of haloperidol (a typical, first-generation antipsychotic drug), risperidone (an atypical, second-ge
233  electrochemical ligand-binding approach for antipsychotic drug screening where competitive binding o
234 results show increasing enrichment for known antipsychotic drugs, selective calcium channel blockers,
235                            Second-generation antipsychotic drugs (SGAs) are essential in the treatmen
236 drugs (FGAs) compared with second-generation antipsychotic drugs (SGAs).
237                                              Antipsychotic drugs should no longer be regarded as an a
238 eral adverse outcomes attributed to atypical antipsychotic drugs, specifically quetiapine, risperidon
239  visits, patients' vital status, and current antipsychotic drug status was collected and reported by
240                                        Other antipsychotic drugs stimulated phosphorylation of a subs
241                                    Data from antipsychotic drug studies indicate that polymorphisms w
242 peated exposure to several stimuli including antipsychotic drugs such as haloperidol.
243                                         Some antipsychotic drugs, such as aripiprazole, are less effi
244                                     Atypical antipsychotic drugs, such as clozapine and risperidone,
245 (5-HT2AR) is a prominent target for atypical antipsychotic drugs, such as clozapine.
246                                              Antipsychotic drugs, such as penfluridol, block PRL sign
247                      The closely related non-antipsychotic drugs, such as ritanserin and methysergide
248                                      Several antipsychotic drugs, such as sertraline, trifluoperazine
249                           Furthermore, newer antipsychotic drugs target 5-HT2AR.
250                                              Antipsychotic drugs target dopamine and serotonin recept
251 ferentially methylated genes and 49 genes as antipsychotic drug targets.
252               Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine receptor
253  relevant randomised controlled trials of 12 antipsychotic drugs that involved 2669 participants.
254                       Among users of typical antipsychotic drugs, the incidence-rate ratios increased
255 e in the actions of the second generation of antipsychotic drugs, the so-called atypical antipsychoti
256 hotic episode who had no previous history of antipsychotic drug therapy began a regimen of olanzapine
257               We identified the FDA-approved antipsychotic drug thioridazine as an EAG2 channel block
258 nd- (sertindole; 2.5 mg/kg, i.p.) generation antipsychotic drug to rapidly induce depolarization bloc
259 e repeated in monkeys chronically exposed to antipsychotic drugs to determine their effect on mitocho
260                   Repeated administration of antipsychotic drugs to normal rats has been shown to ind
261  D2 receptor (D2R) levels and the failure of antipsychotic drugs to rescue adult behavioral defects.
262 t essential either for AMP to disrupt or for antipsychotic drugs to reverse AMP disruption of learnin
263 uthors recently demonstrated that successful antipsychotic drug treatment alters resting-state functi
264  functional connectivity predict response to antipsychotic drug treatment in acutely psychotic patien
265                                     Atypical antipsychotic drug treatment is clinically effective wit
266                         Clinical response to antipsychotic drug treatment is highly variable, yet pro
267 y in the course of illness and the impact of antipsychotic drug treatment on these deficits are not w
268 hibition of the dopamine transporter rescued antipsychotic drug treatment outcomes, supporting the hy
269 phrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic
270                                              Antipsychotic drug treatment, including the atypical clo
271 elated with the clinical efficacy of chronic antipsychotic drug treatment.
272 xhibit initial effects soon after initiating antipsychotic drug treatment.
273 gene is associated with clinical response to antipsychotic drug treatment.
274 tion is associated with clinical response to antipsychotic drug treatment.
275 phrenia tended to have less improvement with antipsychotic drug treatment.
276 ponse in negative and depressive symptoms to antipsychotic drug treatment.
277  polymorphism influences symptom response to antipsychotic drug treatment.
278              Although the currently approved antipsychotic drug treatments, which primarily modulate
279 nited States and Germany and from a European antipsychotic drug trial.
280 ectrometry/mass spectrometry showed that the antipsychotic drug trifluoperazine penetrates well into
281 we repurposed an existing phenothiazine-like antipsychotic drug, trifluoperazine, as a potential anti
282 rect effect was equal to the total effect of antipsychotic drug type (FGA vs. SGA) on mortality risk
283                                     Atypical antipsychotic drug use is associated with an increased r
284                                     Atypical antipsychotic drug use versus nonuse was associated with
285 uding two process measures (catheter use and antipsychotic drug use) and three outcome measures (pres
286  the interaction of chlorpromazine (CPZ), an antipsychotic drug used in the treatment of schizophreni
287 otic drugs as compared with users of typical antipsychotic drugs was 1.14 (95% CI, 0.93 to 1.39).
288                          Chronic exposure to antipsychotic drugs was not associated with changes in b
289                          The prescription of antipsychotic drugs was not significantly different betw
290 elated to factors associated with the use of antipsychotic drugs, we performed a secondary analysis o
291  imprinting of an electroactive aripiprazole antipsychotic drug were herein designed and synthesized.
292                                Some atypical antipsychotic drugs were identified by their high affini
293                                         Some antipsychotic drugs were identified by their high affini
294                    Until recently, all known antipsychotic drugs were thought to block the dopamine D
295 enazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagoni
296 regarding the cardiac safety of the atypical antipsychotic drugs, which have largely replaced the old
297 e performed a secondary analysis of users of antipsychotic drugs who had no baseline diagnosis of sch
298 of UNC9975 and transformed it into a typical antipsychotic drug with a high propensity to induce cata
299                     Thus, proven or putative antipsychotic drugs with different mechanisms of action
300 of sudden cardiac death than did nonusers of antipsychotic drugs, with adjusted incidence-rate ratios

 
Page Top